- Home
- ABLV vs MRSN Comparison
ABLV vs MRSN Comparison
Compare ABLV & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- MRSN
- Stock Information
- Founded
- ABLV 2015
- MRSN 2001
- Country
- ABLV China
- MRSN United States
- Employees
- ABLV N/A
- MRSN N/A
- Industry
- ABLV
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ABLV
- MRSN Health Care
- Exchange
- ABLV Nasdaq
- MRSN Nasdaq
- Market Cap
- ABLV 51.4M
- MRSN 47.1M
- IPO Year
- ABLV N/A
- MRSN 2017
- Fundamental
- Price
- ABLV $0.97
- MRSN $8.15
- Analyst Decision
- ABLV
- MRSN Strong Buy
- Analyst Count
- ABLV 0
- MRSN 3
- Target Price
- ABLV N/A
- MRSN $33.00
- AVG Volume (30 Days)
- ABLV 18.9K
- MRSN 59.5K
- Earning Date
- ABLV 12-19-2025
- MRSN 11-13-2025
- Dividend Yield
- ABLV N/A
- MRSN N/A
- EPS Growth
- ABLV N/A
- MRSN N/A
- EPS
- ABLV 0.05
- MRSN N/A
- Revenue
- ABLV $114,319,869.00
- MRSN $34,769,000.00
- Revenue This Year
- ABLV N/A
- MRSN N/A
- Revenue Next Year
- ABLV N/A
- MRSN N/A
- P/E Ratio
- ABLV $20.35
- MRSN N/A
- Revenue Growth
- ABLV N/A
- MRSN 16.14
- 52 Week Low
- ABLV $0.55
- MRSN $5.21
- 52 Week High
- ABLV $1.77
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- ABLV 51.99
- MRSN 41.12
- Support Level
- ABLV $0.88
- MRSN $8.00
- Resistance Level
- ABLV $0.96
- MRSN $9.87
- Average True Range (ATR)
- ABLV 0.07
- MRSN 0.64
- MACD
- ABLV -0.00
- MRSN -0.31
- Stochastic Oscillator
- ABLV 38.32
- MRSN 5.49
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.